San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor from the weight loss drug industry in February following revealing promising details from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March t